EMERYVILLE, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq:GRTS) today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Gritstone Oncology. In addition, Gritstone Oncology has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Gritstone Oncology’s common stock is expected to begin trading on The Nasdaq Global Select Market on Sept. 28, 2

Indigo Certified Crops™ is a new offer for U.S. growers, integrating the company’s microbial and digital technologies with the newly announced Indigo Marketplace™ The offer aims to increase grower profitability with higher yields and guaranteed premiums on grain sold through Indigo Marketplace™ Growers engaged in Indigo Certified Crops™ retain decision-making authority in the marketing of their grain Boston, Massachusetts, September 20th, 2018 – Indigo Ag, Inc., a company dedicated to harnessing nature to help farmers sustainably feed the planet, announces its newest offering for the 2019 crop season, Indigo Certified Crops™. Indigo Certified Crops was built to provide growers with flexibil

Indigo extends efforts to decommoditize agriculture with launch of Indigo Marketplace™, a digital platform for buying and selling grain Indigo Marketplace has already connected thousands of U.S. growers and buyers, with billions of dollars in inventory and demand Supporting Indigo’s mission and the expansion of Indigo Marketplace is a Series E raise of $250M, bringing Indigo’s total capital raised to over $650M Boston, Massachusetts, September 18, 2018 – Indigo Ag, Inc., a company dedicated to harnessing nature to help farmers sustainably feed the planet, announces the launch of Indigo Marketplace™, along with the close of a $250M Series E funding round. Indigo Marketplace allows the company

ANN ARBOR, Mich., September 13, 2018 – Millendo Therapeutics, Inc., a clinicalstage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases, today announced the initiation of a Phase 2b clinical trial evaluating the efficacy and safety of its novel drug candidate, nevanimibe, in patients with classic congenital adrenal hyperplasia (CAH), a rare inherited endocrine disease characterized by abnormal hormone levels and overgrowth of the adrenal glands. “The advancement of nevanimibe into a Phase 2b trial marks a significant milestone for Millendo as we work to deliver meaningful therapies to patients who do not have sufficient treatment options,” said Juli

Leveraging satellite technology, Indigo releases data on an unprecedented 40,000+ acres from the 2018 commercial wheat harvest Indigo Wheat™ demonstrates median yield gains of 12.7%, with protein content averaging 13.8% Growers of Indigo Wheat™ with a 40 bushel per acre average have the potential to earn $44.20 more per acre in the 2018/2019 season Boston, Massachusetts, September 12, 2018 – Indigo Ag, Inc., a company dedicated to harnessing nature to help farmers sustainably feed the planet, has released 2018 harvest data from over 40,000 acres of wheat grown through Indigo Production™. Wheat grown in contract with Indigo demonstrated median yield gains of 12.7% when compared to neighboring